VK2735 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
VK2735 is an experimental weekly shot from Viking Therapeutics that works on two appetite signals, GLP-1 and GIP. It is in large final-stage studies. A pill version took weight off fast in a short early study.
Evidence grade for VK2735: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 3 completed trials, 4,650 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 4,650
- Human studies
- 3
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
3 completed trials, 4,650 people given it
1 effects reported, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
VK2735 is an experimental weight loss drug from Viking Therapeutics. It works on two hunger signals, GLP-1 and GIP, the same pair as Mounjaro. It is being made as a weekly shot and as a daily pill. It is not approved.
What people take it for
- Fast weight loss.
- A pill instead of a shot.
- Weight loss with type 2 diabetes.
What studies in people showed
In a 13-week study of the weekly shot, people lost 9.1 to 14.7 percent of their weight, depending on the dose. People on a dummy shot lost 1.7 percent. 93 percent of people on the drug lost at least 5 percent. The pill took off up to 12.2 percent in 13 weeks, which is about 26.6 pounds. That pill result came from a company talk, not a paper. Thirteen weeks is short. Two large final-stage studies of the shot run for 78 weeks. One has about 4,650 adults.
What people report
Reports, not study results
The good
- In the studies on this page, weight came off fast, both on the shot and on the pill.
The bad
- The studies on this page do not list side effects, and we have not collected user reports on this one yet.
Where these come from: The good line is from the studies and company reports on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Thirteen weeks tells you it works fast. It does not tell you where you land after a year. It is not approved, so wait.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals VK2735 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 2 studies
35 of the 36 indexed goals have no study of any kind behind VK2735
No study in people, animals or cells on this page reports a result for these. That does not prove VK2735 does nothing for them. It does mean anything you have heard about VK2735 and one of these did not come from a study cited here.
Show full evidence
What is VK2735?
VK2735 is an experimental weekly shot from Viking Therapeutics that works on two appetite signals, GLP-1 and GIP. It is in large final-stage studies. A pill version took weight off fast in a short early study.
VK2735 is an experimental drug from Viking Therapeutics. Like tirzepatide, it works on two appetite and blood sugar signals, GLP-1 and GIP. In a 13-week mid-stage study of the weekly shot, people on the top dose lost about 14.7 percent of their body weight. People on a dummy shot lost 1.7 percent. A pill version took off up to about 12.2 percent in 13 weeks, one of the fastest early results for any pill. Two large final-stage studies of the shot are now fully signed up. VANQUISH-1 has about 4,650 adults and filled in November 2025. VANQUISH-2, in people with type 2 diabetes, filled in March 2026. Each runs 78 weeks. It is not approved.
How does VK2735 work?
It turns on both the GLP-1 and GIP signals. That helps the body release insulin, cuts appetite and slows how fast food leaves the stomach.
The evidence, in charts
Fig. 1a · how many people
4,650people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Viking Therapeutics press release 2025 | 4,650 | 100% |
The whole total is one study of 4,650. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 3 sources here are studies in people.
- Study in people · done in people3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Supports weekly dosing (injectable)
No amino acid sequence is on file for VK2735, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study
A weekly shot stripped off a serious amount of weight, fast. At the top dose people lost about 15 percent of their body weight in 13 weeks, against under 2 percent on a dummy, and more than nine in ten lost at least 5 percent. Thirteen weeks is a short look. It shows the drug does something quickly and says nothing about where people stand a year later.
Weight fell 9.1% to 14.7% across doses at 13 weeks versus 1.7% with placebo; 93% lost at least 5%.
- Study in people2025Viking Therapeutics announces completion of enrollment in Phase 3 VANQUISH-1 trial of VK2735
Nothing has been found here yet. This is an announcement that a large trial finished signing people up in November 2025, around 4,650 adults, who will be followed for 78 weeks. Until it reports, everything known about this drug comes from short middle stage studies. Knowing a trial is running is still worth something when you are deciding what to believe today.
November 19, 2025: about 4,650 adults enrolled in the 78-week Phase 3 VANQUISH-1 trial of weekly subcutaneous VK2735.
- Study in people2026Viking Therapeutics presents data from its 13-week Phase 2 VENTURE-Oral Dosing trial of VK2735 at ECO 2026
A pill version of the drug takes weight off too. Over 13 weeks people lost up to about 12 percent of their body weight, and bigger doses took off more. For those who lost most that is roughly 27 pounds. Two cautions. This is the company presenting its own results rather than a published paper, and 13 weeks is a short window in a field where the questions are about years.
Oral VK2735 produced dose-dependent weight loss up to 12.2% (26.6 lb) at 13 weeks.
Where to buy VK2735
No seller we track lists VK2735 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has VK2735 been tested in people?
Yes. 4,650 people given it across 3 completed trials cited here, 0 of which found nothing. VK2735 is an experimental weekly shot from Viking Therapeutics that works on two appetite signals, GLP-1 and GIP. It is in large final-stage studies. A pill version took weight off fast in a short early study.
What is the VK2735 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 3 completed trials, 4,650 people given it
Is VK2735 FDA-approved?
Investigational. The final-stage VANQUISH-1 and VANQUISH-2 studies have signed up all their people. The pill form has finished mid-stage studies
How is VK2735 different from tirzepatide?
Both work on GLP-1 and GIP. Tirzepatide is approved and given as a shot. VK2735 is still experimental, and it is being made as both a shot and a pill.